OpenAlex
PricingAboutJobs
Log inGet started
Work

ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.

HTML

Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2022.40.16_suppl.tps1120
Authors: Erika P. Hamilton, Anne F. Schott, Rita Nanda, Haolan Lu, Chi Fung Keung, Richard Gedrich, Janaki Parameswaran, Hyo S. Han, Sara A. Hurvitz
Institutions: Sarah Cannon, Tennessee Oncology, U-M Rogel Cancer Center, University of Chicago Medical Center, Arvinas (United States), Moffitt Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English

Topic: Advanced Breast Cancer Therapies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ARV-471, PROTAC degraders, estrogen receptor degradation, palbociclib, CDK4/6 inhibitors, ER+/HER2- breast cancer, advanced breast cancer, endocrine therapy, combination therapy, safety and tolerability, fulvestrant, dose escalation, brain metastases
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4281619002
Cites:
Cited by: 71
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security